In line with this hypothesis, it has been reported that the use of quercetin or flavonoid methyl esters in combination with specific mitogen-activated extracellular kinases (MEK) 1/2 inhibitors substantially enhanced leukemic cell death, confirming the clinical implications for the use of these compounds in combination with MEK 1/2 inhibitors as potential therapeutic agents for leukemia [376]. The gene discussed is MAP2K1; the disease is leukemia.